Table 2.
Cost-effectiveness estimates for women with favorable early-stage breast cancer*
| Model result | Age, y | No RT | EBRT | Incremental changes | IMRT† | Incremental changes, IMRT† |
|---|---|---|---|---|---|---|
| Costs, $, per woman | 70–74 | 20077 | 29500 | 9423 | 37710 | 8209 |
| 75–79 | 24328 | 33774 | 9445 | 41983 | 8209 | |
| 80–94 | 34058 | 43569 | 9510 | 51778 | 8209 | |
| QALY per woman | 70–74 | 5.171 | 5.418 | 0.246 | 5.524 | 0.106 |
| 75–79 | 4.596 | 4.814 | 0.218 | 4.909 | 0.095 | |
| 80–94 | 3.608 | 3.778 | 0.170 | 3.852 | 0.074 | |
| Incremental cost-effectiveness ratio, $/QALY* |
70–74 | — | 38300 | 77100 | ||
| 75–79 | — | 43200 | 86700 | |||
| 80–94 | — | 55800 | 110500 | |||
| All | — | 44600 | 89300 |
* Minor discrepancies may exist because of rounding. EBRT= external beam radiation therapy; IMRT= intensity modulated radiation therapy; QALY=quality-adjusted life-year; RT= radiation therapy.
† Assuming that the recurrence rate is identical in the group receiving EBRT or IMRT and IMRT increases utility by 25% of the difference between utility receiving EBRT without recurrence and utility of healthy women without breast cancer. ICERs are rounded to the nearest hundred.